A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer.

Bangyou ZuoXiaobo YangXu YangJin BianJunyu LongDongxu WangCong NingYanyu WangZiyu XunYunchao WangXin LuYilei MaoXinting SangHaitao Zhao

Published in: Cancer immunology, immunotherapy : CII (2022)

Anti-PD-1 antibodies plus lenvatinib represent an effective and tolerable therapy for patients with advanced gallbladder cancer.

Keyphrases